Your browser doesn't support javascript.
loading
Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.
Lopez-Tarruella, Sara; Del Monte-Millán, María; Roche-Molina, Marta; Jerez, Yolanda; Echavarria Diaz-Guardamino, Isabel; Herrero López, Blanca; Gamez Casado, Salvador; Marquez-Rodas, Iván; Alvarez, Enrique; Cebollero, María; Massarrah, Tatiana; Ocaña, Inmaculada; Arias, Ainhoa; García-Sáenz, José Ángel; Moreno Anton, Fernando; Olier Garate, Clara; Moreno Muñoz, Diana; Marrupe, David; Lara Álvarez, Miguel Ángel; Enrech, Santos; Bueno Muiño, Coralia; Martín, Miguel.
Affiliation
  • Lopez-Tarruella S; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañon (IiSGM), CIBERONC, Geicam, Universidad Complutense, 28007, Madrid, Spain.
  • Del Monte-Millán M; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CiberOnc, Madrid, Spain.
  • Roche-Molina M; Medical Oncology Department, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
  • Jerez Y; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CiberOnc, Madrid, Spain.
  • Echavarria Diaz-Guardamino I; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CiberOnc, Madrid, Spain.
  • Herrero López B; Medical Oncology Department, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
  • Gamez Casado S; Medical Oncology Department, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
  • Marquez-Rodas I; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CiberOnc, Madrid, Spain.
  • Alvarez E; Medical Oncology Department, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
  • Cebollero M; Pathology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Massarrah T; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CiberOnc, Madrid, Spain.
  • Ocaña I; Medical Oncology Department, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
  • Arias A; Medical Oncology Department, Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
  • García-Sáenz JÁ; Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), CIBERONC, Madrid, Spain.
  • Moreno Anton F; Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), CIBERONC, Madrid, Spain.
  • Olier Garate C; Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Alcorcon, Spain.
  • Moreno Muñoz D; Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Alcorcon, Spain.
  • Marrupe D; Department of Oncologia, Hospital Universitario de Móstoles, Mostoles, Spain.
  • Lara Álvarez MÁ; Medical Oncology Department, Hospital Universitario Infanta Leonor, Universidad Complutense, Madrid, Spain.
  • Enrech S; Medical Oncology Department, Hospital Universitario de Getafe, Madrid, Spain.
  • Bueno Muiño C; Medical Oncology Department, Hospital Infanta Cristina (Parla), Fundación de Investigación Biomédica del H.U. Puerta de Hierro, Majadahonda, 28009, Madrid, Spain.
  • Martín M; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañon (IiSGM), CIBERONC, Geicam, Universidad Complutense, 28007, Madrid, Spain. mmartin@geicam.org.
Breast Cancer Res Treat ; 203(1): 163-172, 2024 Jan.
Article in En | MEDLINE | ID: mdl-37773555
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Guideline / Prognostic_studies Limits: Female / Humans Language: En Journal: Breast Cancer Res Treat Year: 2024 Document type: Article Affiliation country: Spain
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Guideline / Prognostic_studies Limits: Female / Humans Language: En Journal: Breast Cancer Res Treat Year: 2024 Document type: Article Affiliation country: Spain